Literature DB >> 19751916

Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's disease patients.

Steven Ferris1, Ralf Ihl, Philippe Robert, Bengt Winblad, Gudrun Gatz, Frank Tennigkeit, Serge Gauthier.   

Abstract

BACKGROUND: Communication problems are common in Alzheimer's disease (AD) patients, but instruments to assess these symptoms are limited. Our objective was to create a new scale, based on the language subscale of the Severe Impairment Battery (SIB), as a sensitive and reliable measurement of treatment effects on language performance.
METHODS: All 24 items of the SIB language subscale were chosen for analysis. Baseline scores of 1320 moderate-to-severe patients (Mini-Mental State Examination [MMSE] score, <15), from a combined AD database of four Memantine clinical trials (Study Codes: IE-2101, MEM-MD-01, MEM-MD-02, and MRZ-9605), were used for item reduction according to a standard principal components factor analysis. All items with loadings >0.5 on the identified factors were selected for inclusion in the new language scale. Correlations with existing AD scales were examined.
RESULTS: The analysis indicated six factors, with 21 of 24 items showing loadings >0.5. The resulting 21-item SIB Language (SIB-L) scale exhibited high internal consistency (Cronbach's alpha = 0.809). The maximal SIB-L score was 41 points, with a measurement error of 3.7 points. The stratification of baseline SIB-L scores (mean, 31.7; SD, 8.4) by MMSE scores (mean, 9.7; SD, 3.3) showed a high variance in SIB-L scores. This confirms that patients with a low MMSE score can possess preserved language abilities. The SIB-L scale did not exhibit substantial floor-and-ceiling effects.
CONCLUSIONS: The new SIB-L is a fast (<15 minutes) and easily administered scale with favorable psychometric characteristics for assessing language impairment and treatment effects on the language performance of patients with moderate to severe AD.

Entities:  

Mesh:

Year:  2009        PMID: 19751916     DOI: 10.1016/j.jalz.2009.04.1236

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  8 in total

1.  Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?

Authors:  Philippe Robert; Steven Ferris; Serge Gauthier; Ralf Ihl; Bengt Winblad; Frank Tennigkeit
Journal:  Alzheimers Res Ther       Date:  2010-08-26       Impact factor: 6.982

2.  Combining drug and music therapy in patients with moderate Alzheimer's disease: a randomized study.

Authors:  Anna Rita Giovagnoli; Valentina Manfredi; Letizia Schifano; Chiara Paterlini; Annalisa Parente; Fabrizio Tagliavini
Journal:  Neurol Sci       Date:  2018-03-17       Impact factor: 3.307

3.  Cognitive Profiles on the Severe Impairment Battery Are Similar in Alzheimer Disease and Down Syndrome With Dementia.

Authors:  Malcolm B Dick; Eric Doran; Michael Phelan; Ira T Lott
Journal:  Alzheimer Dis Assoc Disord       Date:  2016 Jul-Sep       Impact factor: 2.703

4.  Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease.

Authors:  Steven H Ferris; Frederick A Schmitt; Judith Saxton; Sharon Richardson; Joan Mackell; Yijun Sun; Yikang Xu
Journal:  Alzheimers Res Ther       Date:  2011-06-20       Impact factor: 6.982

5.  Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan.

Authors:  Yu Nakamura; Shin Kitamura; Akira Homma; Kazuhito Shiosakai; Daiju Matsui
Journal:  Expert Opin Pharmacother       Date:  2014-03-27       Impact factor: 3.889

Review 6.  Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region.

Authors:  Marwan Sabbagh; SeolHeui Han; SangYun Kim; Hae-Ri Na; Jae-Hong Lee; Nagaendran Kandiah; Kammant Phanthumchinda; Chuthamanee Suthisisang; Vorapun Senanarong; Ming-Chyi Pai; Diatri Narilastri; Ajit M Sowani; Encarnita Ampil; Amitabh Dash
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2016-09-09

Review 7.  Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors.

Authors:  Steven H Ferris; Martin Farlow
Journal:  Clin Interv Aging       Date:  2013-08-02       Impact factor: 4.458

8.  Development of the Experienced Communication in Dementia Questionnaire: A Qualitative Study.

Authors:  Maria W L J Olthof-Nefkens; Els W C Derksen; Bert J M de Swart; Maria W G Nijhuis-van der Sanden; Johanna G Kalf
Journal:  Inquiry       Date:  2021 Jan-Dec       Impact factor: 1.730

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.